Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHansard Regulatory News (HSD)

Share Price Information for Hansard (HSD)

Share Price is delayed by 15 minutes
Get Live Data
52.00    -0.75 (-1.39%)
Bid:
52.00
Ask:
54.50
Spread: 2.50 (4.808%)
Market Cap: £71.00m
HSD Live PriceLast checked at - London Stock Exchange

Intraday Hansard Share Chart

Dr Leonard Polonsky

17 Mar 2025 07:00

RNS Number : 9021A
Hansard Global plc
17 March 2025
 

17 March 2025

 

Hansard Global plc

(Hansard)

 

Hansard Global plc today announces the death (at the age of 97) of its founder, controlling shareholder (under the Leonard Polonsky Revocable Trust) and President, Dr Leonard Polonsky CBE. Dr Polonsky died on Friday 14th March at his home in New York surrounded by loved ones.

Dr Polonsky began working in financial services in New York in 1955, gaining experience of working in Rome, Frankfurt and Zurich, before establishing Liberty Life Assurance Company Limited in London in 1970. Hansard Global plc, its successor, has been listed on the London Stock Exchange since 2006.

A keen philanthropist, Dr Polonsky's legacy will live on through the Polonsky Foundation, a UK-registered charity which supports higher education, cultural heritage and the arts in the UK, the USA, Israel and Europe.

Dr Polonsky's commitment to giving back was recognised in 2013, when he was named a Commander of the British Empire (CBE) for charitable services by HM Queen Elizabeth II.

Known for his charm and creativity, his tireless enthusiasm for Hansard's business and industry, and his deep interest in Hansard's people, Dr Polonsky lived a remarkably full life, earning the respect and admiration of business colleagues, academics and philanthropic beneficiaries across the world.

The Leonard Polonsky Revocable Trust continues to hold Dr Polonsky's shares in the company and is now the controlling shareholder. This Trust was established in 2018 to provide for the orderly control of the shares in the event of Dr Polonsky's death or incapacity.

Policyholders, advisers, employees and all other key stakeholders of the business are assured that, despite this sad news, Hansard will continue to operate as usual.

The management and staff of Hansard share their deepest condolences with Dr Polonsky's family and friends at this sad time.

 

 

 

This announcement contains inside information for the purposes of the UK version of the market abuse regulation (EU no. 596/2014) as it forms part of UK law by virtue of the European union (withdrawal) act 2018 (UK MAR)

 

 

 

Enquiries:

Hansard Global plc +44 (0) 1624 688000

Thomas Morfett, Group CEO

Hazel Stewart, Company Secretary

Email: Investor-relations@hansard.com

 

 

LEI number: 213800ZJ9F2EA3Q24K05

 

 

Notes to editors:

 

· Hansard Global plc is the holding company of the Hansard group of companies. The Company was listed on the London Stock exchange in December 2006. The Group is a specialist long-term savings provider, based in the Isle of Man.

· The Group offers a range of flexible and tax-efficient investment products within a life assurance policy wrapper, designed to appeal to affluent, international investors.

· The Group utilises a controlled cost distribution model via a network of independent financial advisors and the retail operations of certain financial institutions who provide access to their clients in more than 170 countries. The Group's distribution model is supported by Hansard OnLine, a multi-language internet platform, and is scalable.

· The principal geographic markets in which the Group currently services contract holders and financial advisers are the Middle East & Africa, the Far East and Latin America. These markets are served by Hansard International Limited and Hansard Worldwide Limited.

· Hansard Europe dac previously operated in Western Europe but closed to new business with effect from 30 June 2013.

· The Group's objective is to grow by attracting new business and positioning itself to adapt rapidly to market trends and conditions. The scalability and flexibility of the Group's operations allow it to enter or develop new geographic markets and exploit growth opportunities withing existing markets without the need for significant further investment.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCGPUWGWUPAUQM
Date   Source Headline
20th Mar 20263:21 pmRNSInsurance Recovery Received
5th Mar 20267:00 amRNSInterim Results
5th Nov 202511:29 amRNSResult of AGM
29th Oct 20257:00 amRNSHolding(s) in Company
2nd Oct 20258:48 amRNSDirector/PDMR Shareholding
25th Sep 20257:00 amRNSResults for the year ended 30 June 2025
24th Jul 20257:00 amRNSDirectorate Change
17th Mar 20257:00 amRNSDr Leonard Polonsky
6th Mar 20257:00 amRNSInterim Result
17th Dec 20247:00 amRNSDirectorate Change
28th Nov 20247:00 amRNSDirectorate Change
13th Nov 202412:00 pmRNSResult of AGM
22nd Oct 20247:00 amRNSBlock listing Interim Review
2nd Oct 20247:00 amRNSAppointment of Chief Financial Officer
26th Sep 20247:00 amRNSResults for the year ended 30 June 2024
24th Sep 20247:00 amRNSDirectorate Change
2nd Aug 20247:00 amRNSDirectorate Change
1st Jul 20248:46 amRNSTR-1 Notification of Major Holdings
27th Jun 20247:00 amRNSDistribution Agreement
22nd Apr 20249:36 amRNSBlock listing Interim Review
7th Mar 20247:05 amRNSResults for the six months ended 31 December 2023
15th Feb 20247:00 amRNSDirectorate Change
8th Nov 202311:55 amRNSResult of AGM
23rd Oct 20237:24 amRNSBlock listing Interim Review
28th Sep 202311:42 amRNSResults for the year ended 30 June 2023
28th Sep 20237:00 amRNSResults for the year ended 30 June 2023
27th Jul 20237:00 amRNSNew business results for the year ended 30/06/2023
23rd May 20239:27 amRNSDirector/PDMR Shareholding
4th May 20237:00 amRNSTrading Statement
20th Apr 20233:01 pmRNSBlock listing Interim Review
9th Mar 20237:00 amRNSResults for the six months ended 31 December 2022
26th Jan 20237:00 amRNSNew business results for 6 months ended 31/12/22
23rd Jan 20237:00 amRNSDirectorate Change
23rd Nov 20227:00 amRNSDirectorate Change
3rd Nov 20227:00 amRNSTrading update for the quarter ended 30/09/2022
2nd Nov 202212:22 pmRNSResult of AGM
25th Oct 20224:41 pmRNSSecond Price Monitoring Extn
25th Oct 20224:36 pmRNSPrice Monitoring Extension
20th Oct 202211:18 amRNSBlock listing Interim Review
5th Oct 20224:36 pmRNSPrice Monitoring Extension
26th Sep 20224:41 pmRNSSecond Price Monitoring Extn
26th Sep 20224:36 pmRNSPrice Monitoring Extension
22nd Sep 20227:00 amRNSResults for the year ended 30 June 2022
21st Jul 20227:00 amRNSNew business results for the year ended 30/06/2022
20th May 202211:59 amRNSPDMR Shareholding
5th May 20227:00 amRNSTrading update for the period ended 31 March 2022
22nd Apr 20228:30 amRNSBlock listing Interim Review
25th Mar 20229:54 amRNSListing Rule 9.6.14(R) Disclosure
3rd Mar 20227:05 amRNSAppointment of Chairman
3rd Mar 20227:00 amRNSResults for the six months ended 31 December 2021

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.